References
Derk CT (2011) Disease-modifying drugs for systemic sclerosis: why have we not found them yet? Expert Rev Clin Immunol 7:399–401
Mendoza FA, Keyes-Elstein LL, Jimenez SA (2012) Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken) 64:945–954
Geyer M, Müller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40:92–103
Hirschl M, Hirschl K, Lenz M et al (2006) Transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54:1974–1981
Cutolo M, Pizzorni C, Sulli A (2007) Identification of transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon by nailfold videocapillaroscopy. Arthritis Rheum 56:2102–2103
Herrick AL, Cutolo M (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 62:2595–2604
Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37–50
Dulmovits BM, Herman IM (2012) Microvascular remodeling and wound healing: a role for pericytes. Int J Biochem Cell Biol 44:1800–1812
Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54
Distler JH, Jüngel A, Pileckyte M et al (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 561:4203–4215
Müller-Ladner U, Distler O, Ibba-Manneschi L et al (2009) Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 42:587–595
Manetti M, Guiducci S, Matucci-Cerinic M (2011) The origin of the myofibroblast in fibroproliferative vasculopathy: does the endothelial cell steer the pathophysiology of systemic sclerosis? Arthritis Rheum 63:2164–2167
Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210
Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54
Widyantoro B, Emoto N, Nakayama K et al (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121:2407–2418
Nataraj D, Ernst A, Kalluri R (2010) Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 43:129–130
Mouthon L, Mehrenberger M, Teixeira L et al (2011) Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 42:95–102
Soldano S, Montagna P, Brizzolara R et al (2012) Transforming growth factor-β and endothelin-1 induce endothelial-to-mesenchymal transition in cultured human endothelial cells. Arthritis Rheum 64:abstract 1493
Li Z, Jimenez SA (2011) Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelial-to-mesenchymal transition in vitro. Arthritis Rheum 63:2473–2483
Cutolo M, Sulli A, Secchi ME, Pizzorni C (2006) Capillaroscopy and rheumatic diseases: state of the art. Z Rheumatol 65:290–296
Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 71:1636–1639
Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155–160
Avouac J, Fransen J, Walker UA et al (2011) EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70:476–481
LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576
Johnson SR, Fransen J, Khanna D et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64:358–367
Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. Ann Rheum Dis 71:1636–1639
Smith V, De Keyser F, Pizzorni C et al (2011) Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 70:180–183
Sulli A, Pizzorni C, Smith V et al (2012) Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 64:821–825
Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333:137–141
Kuhn A, Haust M, Ruland V et al (2010) Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 49(7):1336–1345
Piera-Velazquez S, Jimenez SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 5(Suppl 1):S7
Guiducci S, Bellando Randone S, Bruni C et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725
Cutolo M, Zampogna G, Vremis L et al (2013) Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 40:40–45
Conflict of interest
The author states that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cutolo, M. Disease modification in systemic sclerosis. Z. Rheumatol. 72, 326–328 (2013). https://doi.org/10.1007/s00393-013-1157-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-013-1157-2